In an ex vivo cytotoxicity assay of AML patient samples, CDA expression was significantly lower in the Ara-C-sensitive group compared with intermediately sensitive or resistant samples and was found to be a strong predictor of Ara-C response [47]. The gene discussed is CDA; the disease is acute myeloid leukemia.